Source link : https://newshealth.biz/health-news/pcsk9-drug-prevents-first-heart-events-in-diabetes-patients-without-atherosclerosis/
NEW ORLEANS — Evolocumab (Repatha) reduced risk of a first major cardiovascular (CV) event in patients with diabetes but no known atherosclerosis in a substudy of the VESALIUS-CV trial. The PCSK9 inhibitor cut relative risk by 31% compared with placebo whether looking at the composite of death from coronary heart disease, myocardial infarction (MI), or […]
The post PCSK9 Drug Prevents First Heart Events in Diabetes Patients Without Atherosclerosis first appeared on News Health.
—-
Author : News Health
Publish date : 2026-03-28 20:45:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8